





#### **Brief biography**







- Bachelors Science Biology + German Studies, Lewis & Clark College / Portland, OR
- MD and PhD from Ludwig-Maximilians-University / Munich
- Key Account Manger → Head of R&D, Deputy Medical Director Serono GmbH / Munich
- Director of Drug Safety Bavarian Nordic / Munich
- Medical Director Vifor Pharma GmbH / Munich
- Global Medical Lead for Ferinject Vifor Pharma Ltd. / Zurich





### We have a long history of innovation

1872



Founding of the Hecht Pharmacy by Caspar Friedrich Hausmann.

1927



Galenica was founded by 16 pharmacists in western Switzerland.

1944



Founding of Vifor Ltd by the pharmacist René Grosclaude. Vifor = La vie (life) et la force (strength).

1977



Galenica takes over the manufacturers Vifor and Cooper, active in the areas of hospital and pharmaceutical products. 1983



Galenica takes over Laboratorien Hausmann AG, specialised in perfusion and sterile solutions as well as iron preparations.

1991



The activities of the former Laboratorien Hausmann AG in the field of pharmaceutical specialities lead to the founding of Vifor (International) AG.

2002



Venofer® is number 1 worldwide.

2008





- Founding of Vifor Pharma with headquarters in Zurich, Switzerland.
- Integration of Aspreva Pharmaceuticals.
  Introduction of Ferinject® in the EU.

2009



Galenica takes over OM Pharma, a fully integrated, specialised Swiss biotechnology and pharmaceutical company. 2010/2011



Galenica and Fresenius Medical Care form a new pharmaceutical company in the area of nephrology – Vifor Fresenius Medical Care Renal Pharma.

2012/2013



The authorization dossier for the new phosphate binder PA21 is filed in the EU, USA, Switzerland and Singapore.

2013



Injectafer® (US brand name of Ferinject®) receives US FDA approval for the treatment of Iron Deficiency Anaemia.

2013



Velphoro® (PA21) receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis.

2014




Galenica lays foundation for Vifor Pharma to become a successful stand-alone global specialty pharma company within 3 to 5 years.

UK/FER/15/0269b January 2016

- © Vifor Pharma




# We are committed to improving the lives of patients around the world








### We supply leading brands for iron therapy



### Organogram – Vifor Pharma Upper Manangement / Executive Committee





### Global Medical Affairs – Responsibilities

#### **Collaboration with:**

- ClinDev to identify critical data gaps and translate to clinical development plans
- Affiliates and partners
- Global KOLs and critical external audiences

#### **Provision of:**

- Medical and scientific expertise for Development and Commercial
- Expertise and insights into disease areas, latest medical developments, KOL insights and the competitive environment

## Leadership of overall Medical Affairs strategy for assigned brand/therapeutic areas

#### **Ensuring best practice:**

Compliance with EFPIA and local codes and regulations

Crucial to have support of an informed, reliable, compliant agency!

#### Taking action:

- Review of external study proposals and IITs and presentation for review and approval
- Ensure conduct of the Global plans, including delivery of symposia, publications, advisory boards etc.

Deliverables demanding significant resources not available in-house for preparation, conduct and follow-through


#### Global Medical Affairs – Deliverables 2015



500 participants at a CME-accredited event



Support for local affiliates running CME events for 200–500 participants










### Typical work week...



### Agency support













